Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present Ra Pharmaceuticals, Inc. (NASDAQ: RARX).

Full DD Report for RARX

You must become a subscriber to view this report.


Recent News from (NASDAQ: RARX)

Ra Pharmaceuticals to Present at the 23rd Congress of the European Hematology Association
Ra Pharmaceuticals, Inc. (NASDAQ:RARX) today announced that data from the Company’s oral, small molecule, complement C5 inhibitor program and data from the Company’s global, Phase 2 clinical program evaluating RA101495 SC for the treatment of paroxysmal nocturnal hemoglobinuria...
Source: Business Wire
Date: May, 17 2018 09:48
Institutional Top Ideas Series: Ra Capital Management
In the last entry of this series we took a look at top ideas from Orbimed Advisors, a large fund in the midst of a leadership transition which avoids outsized bets (over 5% weighting) yet still has posted decent returns. Going forward, I hope to continue to delve into the portfolios of su...
Source: SeekingAlpha
Date: May, 10 2018 02:04
Ra Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate Update
Ra Pharmaceuticals, Inc. (NASDAQ:RARX) today announced financial results for the first quarter ended March 31, 2018 and provided an update on recent corporate and clinical developments. “We continue to make important progress in advancing our lead clinical candidate RA101495 SC in...
Source: Business Wire
Date: May, 09 2018 16:30
Ra Pharmaceuticals to Present at the Deutsche Bank 43rd Annual Health Care Conference
Ra Pharmaceuticals, Inc.  (NASDAQ:RARX), a clinical stage biopharmaceutical company focusing on the development of next-generation therapeutics for the treatment of complement-mediated diseases, today announced that Doug Treco, Ph.D., President and Chief Executive Officer, will present...
Source: Business Wire
Date: May, 01 2018 07:00
Ra Pharmaceuticals Announces Presentation of RA101495 SC Phase 2 gMG Clinical Trial Design at the 70th Annual AAN Meeting
Phase 2 gMG Patient Enrollment on Target Ra Pharmaceuticals, Inc. (NASDAQ:RARX) today announced that the design of its Phase 2 clinical trial of RA101495 SC as a treatment for generalized myasthenia gravis (gMG) will be presented in an oral platform presentation at the 70 th Annual...
Source: Business Wire
Date: April, 25 2018 07:00
Ra Pharmaceuticals Appoints John C. King as Chief Commercial Officer
Ra Pharmaceuticals, Inc. (NASDAQ:RARX), a clinical stage biopharmaceutical company focusing on the development of next-generation therapeutics for the treatment of complement-mediated diseases, today announced the appointment of John C. King as Chief Commercial Officer, effective April 16, 2...
Source: Business Wire
Date: April, 18 2018 07:00
Achillion, Omeros, Ra Rx, Reata, Chemocentryx And Others In The IgA Nephropathy Space
I began this article with the intent of an Achillion Pharmaceuticals ( ACHN ) focus. However, as I learned more about each of these 5 companies, I've decided to give an equal spotlight to each. I will preface the real reason for this renal-focused article is due to my own diagnosis of IgA neph...
Source: SeekingAlpha
Date: April, 09 2018 13:39
Recent Analysis Shows Jack Henry & Associates, Omnicell, Surgery Partners, Floor & Decor, NVE, and RA PHARMCTL INC Market Influences - Renewed Outlook, Key Drivers of Growth
NEW YORK, April 02, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Jack Henry & Associates, Inc. (NASDAQ:JKHY), Omnicell, Inc. (NASDAQ:...
Source: GlobeNewswire
Date: April, 02 2018 08:15
Alexion's long-acting PNH candidate ALXN1210 on par with Soliris in late-stage study; shares up 11% premarket
Alexion Pharmaceuticals (NASDAQ: ALXN ) is up  11%  premarket on light volume in response to its announcement of successful results from a Phase 3 clinical trial assessing ALXN1210 in patients with paroxysmal nocturnal hemoglobinuria (PNH). More news on: Alexion Pharmaceuticals...
Source: SeekingAlpha
Date: March, 15 2018 07:30
Ra Pharmaceuticals beats by $0.01
Ra Pharmaceuticals (NASDAQ: RARX ): Q4 EPS of -$0.67 beats by $0.01 . Cash and cash equivalents of $70.38M Press Release More news on: Ra Pharmaceuticals, Earnings news and commentary, Healthcare stocks news, ,
Source: SeekingAlpha
Date: March, 14 2018 16:37

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-176.366.276.466.21102,610

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-05-216,65938,85717.1372Cover
2018-05-183,50115,44822.6631Cover
2018-05-174,51218,56324.3064Cover
2018-05-166,76021,71331.1334Cover
2018-05-152,9388,86933.1266Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on RARX.


About Ra Pharmaceuticals, Inc. (NASDAQ: RARX)

Logo for Ra Pharmaceuticals, Inc. (NASDAQ: RARX)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $202,114,642 - 05/11/2018
  • Issue and Outstanding: 32,286,684 - 03/02/2018

 


Recent Filings from (NASDAQ: RARX)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 09 2018
Securities offered to employees under employee benefit plans
Filing Type: S-8Filing Source: edgar
Filing Date: May, 09 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 09 2018
Prospectus filed under Rule 424(b)(5)
Filing Type: 424B5Filing Source: edgar
Filing Date: May, 09 2018
Information for Proxy Statement under Rule 14a-101
Filing Type: DEFR14AFiling Source: edgar
Filing Date: May, 07 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 27 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 27 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 14 2018
Amendment to a SC 13D filing
Filing Type: SC 13D/AFiling Source: edgar
Filing Date: March, 02 2018
Amendment to a SC 13D filing
Filing Type: SC 13D/AFiling Source: edgar
Filing Date: February, 27 2018

 

 


Daily Technical Chart for (NASDAQ: RARX)

Daily Technical Chart for (NASDAQ: RARX)


Stay tuned for daily updates and more on (NASDAQ: RARX)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: RARX)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

Monsta Trader
@MonstaTrader

 

 


Disclaimer: Monsta Trader publishes reports providing information on selected companies. Monsta Trader is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. Monsta Trader accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in RARX is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. Monsta Trader has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. Monsta Trader does not own any shares of RARX and does not buy, sell, or trade any shares of RARX. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by Monsta Trader. All rights reserved. Our Full Disclaimer: http://monstatrader.com/disclaimer/